1. Home
  2. WHWK vs ALXO Comparison

WHWK vs ALXO Comparison

Compare WHWK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Whitehawk Therapeutics Inc.

WHWK

Whitehawk Therapeutics Inc.

SELL

Current Price

$3.01

Market Cap

164.8M

Sector

Health Care

ML Signal

SELL

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

SELL

Current Price

$0.97

Market Cap

172.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WHWK
ALXO
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.8M
172.8M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
WHWK
ALXO
Price
$3.01
$0.97
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
★ $7.71
$4.60
AVG Volume (30 Days)
366.3K
★ 1.1M
Earning Date
11-09-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 86.02
26.36
EPS
N/A
★ N/A
Revenue
★ $7,145,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.97
$0.86
52 Week High
$5.50
$2.66

Technical Indicators

Market Signals
Indicator
WHWK
ALXO
Relative Strength Index (RSI) 40.04 37.77
Support Level $2.88 $0.86
Resistance Level $3.88 $1.34
Average True Range (ATR) 0.21 0.15
MACD 0.01 -0.01
Stochastic Oscillator 12.50 14.25

Price Performance

Historical Comparison
WHWK
ALXO

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: